| NCT ID | NCT06674382 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Myelofibrosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 39 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 39 participants in total. It began in 2024-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF. Allogeneic stem cell transplantation (allo-HSCT) is the only potential cure, though limited donor availability restricts access. Haploidentical transplantation shows promise but associated with higher graft failure and treatment related mortality. We recently developed a novel regimen of haplo-SCT for MF. This study aims to investigate this novel protocol in a prospective trial to improve MF outcomes.
Eligibility Criteria
Inclusion Criteria: * Primary disease type: Myelofibrosis (including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or essential thrombocythemia). * No matched sibling donor or unrelated donor, with the availability of a haploidentical donor. * Signed informed consent. Exclusion Criteria: 1. Active infection 2. Very poor performance status (ECOG score \> 2) 3. Estimated survival time \< 30 days 4. Patient or family unable to cooperate 5. Considered unsuitable after discussion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06674382 clinical trial?
This trial is open to participants of all sexes, studying Myelofibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06674382 currently recruiting?
Yes, NCT06674382 is actively recruiting participants. Contact the research team at sunyuqian83@hotmail.com for enrollment information.
Where is the NCT06674382 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06674382 clinical trial?
NCT06674382 is sponsored by Peking University People's Hospital. The trial plans to enroll 39 participants.